Information Provided By: 
Fly News Breaks for January 15, 2019
ARRY
Jan 15, 2019 | 07:38 EDT
Cantor Fitzgerald analyst Varun Kumar started Array BioPharma with an Overweight rating and $30 price target. The stock currently trades at a "significant discount" as its lead asset, Mektovi plus Braftovi, still appears underappreciated by investors, Kumar tells investors in a research note. The analyst believes Array's MEK/BRAFi combination has a "best-in-class" profile and is well positioned commercially in BRAF-mutant melanoma and clinically in BRAF-mutant colorectal cancer.
News For ARRY From the Last 2 Days
ARRY
Apr 24, 2024 | 11:02 EDT
Wells Fargo notes that a group of seven domestic solar product makers, including First Solar (FSLR), filed a petition to levy anti-dumping and countervailing duties on solar imports from Cambodia, Malaysia, Thailand and Vietnam, looking for duties ranging from 70.4% to 271.5%. The firm, which included the "important reminder" that "this is just a petition," says the uncertainty created by the petition is "incrementally positive" for First Solar and negative for Canadian Solar (CSIQ), Array Technologies (ARRY) and Nextracker (NXT).
